Apogee Therapeutics, Inc.APGENASDAQ
Loading

Latest News

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
globenewswire.com

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 16-week data expected in Q2 2026 - Phase 3 trial initiation in AD anticipated in 2H 2026 - Successful expansion of zumilokibart beyond AD demonstrated in asthma Phase 1b trial; details on asthma and eosinophilic esophagitis ( EoE) trials expected later this year Phase 1b head-to-head trial of APG279 (zumilokibart + APG990) vs. DUPIXENT underway, with interim AD data anticipated in 2H 2026 Strong total cash position of $902.9 million with runway into 2H 2028 supports advancement toward potential launch of zumilokibart in 2029 SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and reported fourth quarter and full year 2025 financial results.

Apogee Therapeutics to Participate in Upcoming March Conferences
globenewswire.com

Apogee Therapeutics to Participate in Upcoming March Conferences

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026.

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE
defenseworld.net

Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE

Exane Asset Management acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 51,543 shares of the company's stock, valued at approximately $2,048,000. Apogee Therapeutics comprises 0.7% of Exane Asset Management's investment portfolio, making

Apogee Therapeutics: 2026 Inflection Point In Immunology
seekingalpha.com

Apogee Therapeutics: 2026 Inflection Point In Immunology

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash position provides operational runway into 2028, supporting pivotal Phase II/III trials without near-term dilution risk. Zumilokibart's extended half-life and clean safety profile position APGE to challenge Dupixent, with physician surveys indicating strong preference for reduced dosing frequency.

Carl Dambkowski Sells 18,700 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock
defenseworld.net

Carl Dambkowski Sells 18,700 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 18,700 shares of the firm's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the completion of the sale, the insider owned 212,523 shares of the company's

Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose
defenseworld.net

Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose

Apogee Therapeutics (NASDAQ: APGE) presented interim Phase 1b data for its IL-13 antibody zumilokibart (APG777) in mild to moderate asthma, highlighting what the company described as a robust and durable reduction in fractional exhaled nitric oxide (FeNO) following a single dose. Executives positioned the readout as the first of four key clinical catalysts expected in 2026

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
globenewswire.com

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued development in asthma testing every 3- or 6-month dosing

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
globenewswire.com

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.